50 programming-"the"-"DAAD"-"IMPRS-ML"-"FEMTO-ST"-"P"-"BioData"-"Prof" "Dr" positions at University of Manchester
Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
on the nuclear site. The post holder will work in Dr. Bruno Adorno’s group. What will you get in return: Fantastic market leading Pension scheme Excellent employee health and wellbeing services including
-
, (iii) manage the computational/operational system for CO2 capture devices. The successful candidate would also be expected to work alongside the Principal Investigator (Dr Zhen Xu) to make sure the
-
the electrochemical system, (ii) testing their ability to remove CO2, (iii) understanding the CO2 removal mechanism. The successful candidate would also be expected to work alongside the Principal Investigator (Dr Zhen
-
on regenerative medicine and the understanding of congenital heart disease (CHD). Funded through a prestigious UKRI Future Leaders Fellowship awarded to Dr Matthew Birket (“Understanding Cardiac
-
leading Pension scheme Excellent employee health and wellbeing services including an Employee Assistance Programme Exceptional starting annual leave entitlement, plus bank holidays Additional paid closure
-
the guidance of Dr Mahetab Amer and in collaboration with academic and clinical partners in Manchester and across the UK; this will include working with clinical samples in accordance with governance procedures
-
Summary This is an outstanding opportunity for a Research Associate to work within the Leukaemia Stem Cell Niche (LSCN) group under the supervision of Dr Simona Valletta, based at both the Oglesby
-
essential for this role, as will experience of qualitative research methods. The postholder will work with Professor Paul Wilson, Dr Laura Sheard and other members of the NIHR ARC team and will be based in
-
scheme Excellent employee health and wellbeing services including an Employee Assistance Programme Exceptional starting annual leave entitlement, plus bank holidays Additional paid closure over
-
myelomonocytic leukaemia (CMML) is a blood cancer with few therapeutic options and dismal prognosis. Dr. Daniel Wiseman led a Phase 2 clinical trial (“AMMO”), testing the second-generation, orally-bioavailable